Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHA:600613)

SHA:600613 Revenue

Shanghai Shenqi Pharmaceutical Investment Management had revenue of 425.19M CNY in the quarter ending June 30, 2026, a decrease of -11.59%. This brings the company's total for the last twelve months to 1.84B, down -3.14% year-over-year. In the year 2025, Shanghai Shenqi Pharmaceutical Investment Management had annual revenue of 1.95B, down -4.71%. That makes Shanghai Shenqi Pharmaceutical Investment Management the 15,108th largest company in the world by revenue and 2,721st in China.

• Revenue (ttm): 1.84B
• Revenue Growth: -3.14%
• P/S Ratio: 1.73
• Revenue / Employee: 1.54M
• Employees: 1,196
• Market Cap: 3.19B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Pharmaceutical Manufacturing 1.12B 57.5%
• Pharmaceutical Business 829.28M 42.5%

Fiscal year ended Dec 31, 2025 See the full SHA:600613 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.95B	-96.44M	-4.71%
Dec 31, 2024	2.05B	-292.14M	-12.48%
Dec 31, 2023	2.34B	-47.67M	-2.00%
Dec 31, 2022	2.39B	85.58M	3.72%
Dec 31, 2021	2.30B	484.03M	26.61%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 25, 2026

Data Sources Report a data error